Clonidine

Generic, cheap, non-selective α2-adrenergic agonist that shuts down central sympathetic outflow — heavy sedation, lower BP, slower HR, quieter mind. Originally developed as a nasal decongestant in the 1960s, repurposed for hypertension (1974), then off-label for ADHD, opioid withdrawal, hot flashes, PTSD nightmares, and sleep onset. For Dylan, this is the heavier, less-selective sibling of guanfacine — same wrong-vector problem (sedating in a stack built for alertness) plus worse sedation, shorter half-life, and the rebound-hypertension-on-abrupt-cessation risk that requires a taper if used >1-2 weeks daily. WATCH-LIST PRN at most: niche utility for stim-rebound mitigation, sleep-onset rescue, or somatic anxiety in propranolol-contraindicated contexts. Propranolol PRN, daridorexant, and tryptophan all do their respective jobs better.

Clonidine is the prototype non-selective α2-adrenergic agonist — discovered at Boehringer Ingelheim in the early 1960s as a candidate nasal decongestant (it does cause vasoconstriction at peripheral α2B sites at high doses), and famously repurposed when an investigator's wife took it as a "cold remedy" and slept for 24 hours. The unexpected sedation and BP-lowering pointed to central α2 agonism, and Catapres was approved for hypertension in 1974.

The α2-receptor subtype story (this is the load-bearing distinction vs guanfacine):

α2 receptors come in three subtypes — α2A, α2B, α2C — distributed across the body:

• α2A: Predominant in locus coeruleus, prefrontal cortex pyramidal cells, and brainstem cardiovascular nuclei. Presynaptic α2A autoreceptors on noradrenergic neurons provide negative feedback that reduces NE release. Postsynaptic α2A on PFC dendritic spines is Arnsten's "PFC executive function" target (see guanfacine).
• α2B: Predominantly peripheral vascular smooth muscle; activation produces transient vasoconstriction (the "pressor effect" seen with rapid IV α2 agonist administration).
• α2C: Mostly CNS; modulates dopamine and emotional processing; activation contributes to sedation.

Clonidine binds all three subtypes roughly equally (slight α2A preference, ~3-5×). Guanfacine has ~15-20× selectivity for α2A. This selectivity difference is the load-bearing fact for clinical differentiation:

• Clonidine → broad α2 hit → stronger sedation (α2C), more peripheral effects (α2B), broader sympathetic dampening.
• Guanfacine → α2A-targeted → less sedation, cleaner PFC effect, longer half-life from different molecular structure.

Plus: clonidine has a second mechanism — imidazoline I1 receptor agonism. The rostral ventrolateral medulla (RVLM) contains I1 receptors that, when activated, reduce sympathetic outflow independently of the α2 pathway. Clonidine is a moderate I1 agonist; this contributes to its BP-lowering effect and is part of why moxonidine and rilmenidine (more I1-selective drugs) were developed as next-generation antihypertensives with less sedation than clonidine.

Three primary clinical effects, three mechanisms:

1. Lower BP and HR (α2A presynaptic autoreceptors in LC + I1 receptors in RVLM) — reduced central sympathetic outflow → less peripheral vasoconstriction, slower HR, lower cardiac output. This is the original antihypertensive mechanism.

2. Sedation (α2A in LC + α2C in CNS) — locus coeruleus is the brain's NE switchboard for arousal; clonidine clamps it down, producing deep sedation. This is the dominant subjective effect at any clinically useful dose.

3. Anti-anxiety / quieting (α2A presynaptic LC + amygdala α2 effects) — reduced NE release dampens the noradrenergic drive that fuels hyperarousal, intrusive thoughts, and somatic anxiety. The same mechanism Brunet's reconsolidation work targets with propranolol, but from the upstream side (clonidine reduces NE output) vs the downstream side (propranolol blocks NE receptors).

The "stim-rebound" / opioid-withdrawal use case mechanism: Both stimulant withdrawal and opioid withdrawal involve noradrenergic surge from the locus coeruleus (rebounding from chronic suppression in opioid case; rebounding from sympathetic exhaustion in stim case). Clonidine clamps LC firing directly — so it suppresses the autonomic and subjective signature of withdrawal (anxiety, sweating, tachycardia, agitation, restlessness, pupillary dilation). This is why it's been a workhorse opioid-detox drug for decades.

Pharmacokinetics:

• Tmax: 1-3 hr (immediate-release tablet); 7-8 hr (Kapvay ER); patch (Catapres-TTS): steady-state by ~3 days.
• Half-life: 12-16 hr (adults); shorter in children (~6 hr) — this is the key difference vs guanfacine (17 hr) for the dosing-frequency question.
• Bioavailability: ~75-85% oral; transdermal patch delivers ~50%.
• Protein binding: 20-40% (low — much less than propranolol).
• CNS penetration: High (lipophilic, freely crosses BBB).
• Metabolism: ~50% hepatic (primarily CYP2D6); 50% renal unchanged. Less CYP3A4-dependent than guanfacine.
• Excretion: ~65% renal (40-60% unchanged), ~22% biliary/fecal.
• Onset of subjective effect: Sedation within 30-60 min PO; BP-lowering peak 2-4 hr.

The 20-year-old Dylan-context interpretation: Clonidine is the broader, blunter tool in the α2-agonist family. For Dylan's V4/V5 stack — built around modafinil, bromantane, peptides, and daytime alertness/output — clonidine's central sympathetic shutdown is a hard pharmacodynamic mismatch on a daily basis. The PRN niches (stim-rebound, sleep onset rescue, opioid detox bridging if ever needed, somatic anxiety where propranolol is contraindicated) are real but each one is better-served by a more targeted tool: propranolol PRN for somatic anxiety, daridorexant/tryptophan for sleep onset, no current need for opioid detox or stim-rebound mitigation.